Top 50 Health Care VC Funds & Investors in Belgium (August 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
PMV
VC Fund
|
25 | Belgium, United States, The Netherlands | Seed, Series A, Series B | Software, Biotechnology, Health Care | $1M–$42M |
|
Meusinvest (Noshaq)
VC Fund
|
23 | Belgium, France, Germany | Series A, Seed, Series B | Biotechnology, Health Care, Medical | $137k–$31M |
|
S.R.I.W.
VC Fund
|
16 | Belgium, United States, Spain | Series A, Series B | Health Care, Biotechnology, Manufacturing | $411k–$75M |
|
Gemma Frisius Fund
VC Fund
|
16 | Belgium, France, United Kingdom | Seed, Series A, Series B | Biotechnology, Medical, Health Care | $634k–$84M |
|
V-Bio Ventures
VC Fund
|
14 | Belgium, France, United States | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $3.1M–$88M |
|
Capricorn Partners
VC Fund
|
13 | Belgium, The Netherlands, United States | Series A, Series B | Biotechnology, Health Care, Software | $3.3M–$42M |
|
Qbic Fund
VC Fund
|
12 | Belgium, The Netherlands | Seed, Series A | Biotechnology, Software, Health Care | $906k–$28M |
|
Vives Louvain Technology Fund
VC Fund
|
11 | Belgium, France, United States | Series A, Series B, Seed | Health Care, Biotechnology, Medical | $491k–$125M |
|
VIB
VC Fund
|
11 | Belgium, Brazil, Denmark | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $3.1M–$84M |
|
WING by Digital Wallonia
VC Fund
|
9 | Belgium | Seed, Series A, Convertible Note | Software, Health Care, Information Technology | $219k–$11M |
|
Newton Biocapital
VC Fund
|
9 | Belgium, Japan, France | Series A, Seed | Biotechnology, Medical, Health Care | $2.7M–$84M |
|
Limburgse Reconversie Maatschappij
VC Fund
|
9 | Belgium, The Netherlands, United States | Seed, Series A | Information Technology, Software, Biotechnology | $494k–$11M |
|
Sambrinvest
VC Fund
|
8 | Belgium, France, Spain | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $544k–$46M |
|
White Fund
VC Fund
|
8 | Belgium, United States | Seed, Series A, Venture - Series Unknown | Health Care, Medical, Medical Device | $4.1M–$12M |
|
Inventures SA
VC Fund
|
8 | Belgium, France, United Kingdom | Series A, Seed | Health Care, Biotechnology, Manufacturing | $82k–$14M |
|
KBC
VC Fund
|
7 | Belgium, United States, The Netherlands | Seed, Series A, Pre-Seed | Biotechnology, Health Care, Software | $425k–$65M |
|
EQT Life Sciences
VC Fund
|
7 | United States, The Netherlands, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $7.3M–$165M |
|
Vesalius Biocapital Partners
VC Fund
|
6 | Belgium, Germany, France | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $3.9M–$100M |
|
Gimv
VC Fund
|
6 | Belgium, United States, France | Series B, Series A | Biotechnology, Health Care, Medical | $3.3M–$79M |
|
Spinventure
VC Fund
|
6 | Belgium | Series A | Health Care, Biotechnology, Medical | $768k–$15M |
|
imec.istart Future Fund
VC Fund
|
5 | Belgium, United Kingdom | Seed, Pre-Seed, Series A | Health Care, Medical Device, Satellite Communication | $1.2M–$5.7M |
|
SFPIM
VC Fund
|
5 | Belgium, France, Switzerland | Series A, Venture - Series Unknown | Biotechnology, Health Care, Semiconductor | $8.6M–$251M |
|
Boehringer Ingelheim Venture Fund
VC Fund
|
4 | United States, Germany, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $1.8M–$50M |
|
HERAN Partners
VC Fund
|
4 | United Kingdom, Belgium, The Netherlands | Series A, Seed | Health Care, Artificial Intelligence, Hospital | $2M–$23M |
|
Droia Ventures
VC Fund
|
4 | United States, Belgium, The Netherlands | Series A, Series B, Series C | Biotechnology, Medical, Therapeutics | $12M–$125M |
|
Omnes Capital
VC Fund
|
4 | France, Germany, United States | Series A, Series B | Software, Biotechnology, Health Care | $3.5M–$53M |
|
Mérieux Equity Partners
VC Fund
|
4 | France, United States, Belgium | Series A, Private Equity | Health Care, Biotechnology, Medical Device | $5.7M–$150M |
|
Kurma Partners
VC Fund
|
4 | France, Switzerland, Spain | Series A, Seed, Series B | Health Care, Biotechnology, Medical | $2.7M–$98M |
|
Fund+
VC Fund
|
4 | Belgium, United States, Spain | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $11M–$401M |
|
New Science Ventures
VC Fund
|
4 | United States, United Kingdom, Belgium | Series B, Series A, Series D | Biotechnology, Health Care, Medical | $4M–$52M |
|
AdBio partners
VC Fund
|
3 | France, Spain, Belgium | Seed, Series A, Venture - Series Unknown | Biotechnology, Health Care, Pharmaceutical | $2.2M–$37M |
|
WE International
VC Fund
|
3 | Belgium, United States, France | Seed, Series A, Venture - Series Unknown | Health Care, Energy, Biotechnology | $2.2M–$251M |
|
TCD Capital
VC Fund
|
3 | Belgium, France | Series A, Series B, Venture - Series Unknown | Biotechnology, Health Care, Medical Device | $2.1M–$18M |
|
Volta Ventures
VC Fund
|
3 | Belgium, The Netherlands, United States | Seed, Series A, Pre-Seed | Software, Information Technology, SaaS | $850k–$10M |
|
b2venture
VC Fund
|
3 | Germany, Switzerland, United Kingdom | Series A, Seed, Series B | Software, Health Care, Information Technology | $1.3M–$52M |
|
BioGeneration Ventures
VC Fund
|
3 | The Netherlands, United States, Belgium | Series A, Seed | Biotechnology, Therapeutics, Health Care | $1.1M–$86M |
|
Theodorus III
VC Fund
|
3 | Belgium, Canada, France | Series A, Seed | Health Care, Biotechnology, Life Science | $2.2M–$41M |
|
Spreds
VC Fund
|
3 | Belgium, France | Series A, Seed, Pre-Seed | Information Technology, E-Commerce, Health Care | $150k–$2.5M |
|
Be Angels
VC Fund
|
3 | Belgium, France, Luxembourg | Seed, Pre-Seed | SaaS, Software, Information Technology | $78k–$1.5M |
|
Forbion Capital Partners
VC Fund
|
3 | United States, United Kingdom, The Netherlands | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $16M–$180M |
|
Novo Holdings
VC Fund
|
3 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9.9M–$135M |
|
Ackermans & van Haaren
VC Fund
|
3 | Belgium, India, Germany | Series B, Seed, Series A | Health Care, Medical, Biotechnology | $3.4M–$72M |
|
Miles Ahead
VC Fund
|
3 | Belgium, Ireland, United Kingdom | Seed, Pre-Seed | Software, Big Data, Robotics | $1M–$3.3M |
|
Qbic
VC Fund
|
3 | Belgium | Seed, Series B | Health Care, Biotechnology, AgTech | $3.7M–$12M |
|
Buysse & Partners
VC Fund
|
3 | Belgium, United Kingdom, The Netherlands | Series A, Seed, Venture - Series Unknown | Software, Cloud Computing, FinTech | $1.1M–$11M |
|
Fountain Healthcare Partners
VC Fund
|
3 | Ireland, United States, France | Series A, Series B, Series C | Health Care, Biotechnology, Medical | $3.3M–$110M |
|
Namur Invest
VC Fund
|
3 | Belgium, United States | Series A, Seed | Health Care, Medical Device, Auctions | $658k–$18M |
|
imec.xpand
VC Fund
|
3 | Belgium, United States, Germany | Seed, Series A, Series B | Semiconductor, Manufacturing, Medical Device | $3.3M–$100M |
|
GoBeyond
VC Fund
|
3 | Switzerland, Germany, United Kingdom | Seed, Series A | Information Technology, Medical, Software | $544k–$10M |
|
Thuja Capital
VC Fund
|
3 | The Netherlands, Belgium, United States | Series A, Seed | Biotechnology, Medical, Health Care | |
| Access all 405 VC funds in Belgium Health Care startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Do and dare company
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A, Series B
- Geography: Belgium, United States, The Netherlands
Investor stats
- Total investments: 156
- Round size: Seed $1M–$3.8M; Series A $2.7M–$40M; Series B $6.6M–$42M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- Biotalys — Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combinethe high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium.
- Borro — Cashless deposit system
- Storm — Storm is een producent van hernieuwbare energie. Samen met ons team ontwikkelen, bouwen en exploiteren we duurzame energieprojecten over het hele land: van wind- en zonneparken tot snellaadstations en batterijopslag. Dit telkens tegen een zo laag mogelijke maatschappelijke kost.
Noshaq offers financial services to help businesses develop.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Series B
- Geography: Belgium, France, Germany
Investor stats
- Total investments: 78
- Round size: Seed $137k–$6M; Series A $3.6M–$16M; Series B $680k–$31M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- TrustUp — TrustUp is the home contractors platform, connects homeowners with verified quality home improvement.
- Le Fourgon — Le Fourgon provides contained drinks for home delivery. They offer milk, water, beer, wine, fruit juice, and sodas. They allow customers to have their drinks delivered free of charge during the day.
- Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
The S.R.I.W. Group is an institution at the heart of the financial market that assists entrepreneurs in creating and developing businesses in the Walloon region. It reflects the effort of Wallonian industry in facing the challenges of the creation of economic value in the 21st century. Since its creation in 1979, the Société Régionaled’Investissement de Wallonie has continuously been expanding its abilities to adapt and anticipate as well as its flexibility in order to meet the requirements of its partners who are confronted with the evolution of the world economy. The principles of good governance, a strong business culture and shared values at the heart of the Group constitute important assets to capture the changing realities of the market and progress in a sustainable development perspective.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Manufacturing
- Stage:Series A, Series B
- Geography: Belgium, United States, Spain
Investor stats
- Total investments: 111
- Round size: Series A $411k–$31M; Series B $1.6M–$75M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- Univercells — Mix parlay, atau lebih dikenal sebagai parlay bola atau hanya parlay, merupakan taruhan judi bola online yang menggabungkan minimal 2 hingga 10 tim pertandingan sepak bola menjadi 1 tiket taruhan.
- Intressa Vascular — Intressa Vascular provides innovative solutions to address life-threatening cardiovascular conditions such as aortic dissection.
- Santero Therapeutics — This is the homepage of the website
Gemma Frisius Fund KU Leuven is a seed capital fund that aims to stimulate the creation and growth of university related spin-off companies.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Seed, Series A, Series B
- Geography: Belgium, France, United Kingdom
Investor stats
- Total investments: 40
- Round size: Seed $634k–$4.6M; Series A $932k–$84M; Series B $4.7M–$24M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Runeasi — The first scientifically validated wearable solution to measure impact while running and detect how your body responds to it - Perform real-time biomechanical assessments - Guide your athletes and patients with actionable insights to help them run more efficiently and recover from injuries with confidence
- Optiflux — Optiflux automatiseert het bewaarbeheer van vers fruit met slimme AI & vision-technologie. Minder verlies, meer winst voor teler & handelaar.
- Aspect Analytics — Beyond bioinformatics. Building intelligent platform solutions for mass spectrometry imaging data analysis. #AI4MSI
V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biotech, pharmaceutical and agriculturalsectors.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: Belgium, France, United States
Investor stats
- Total investments: 44
- Round size: Seed $3.1M–$50M; Series A $6.6M–$70M; Series B $12M–$88M
- Lead/follow: 34% lead, 66% follow
- Last fund: May invest from a new fund soon — raised $129M in 2021
Portfolio highlights
- Animab — Animal Health Company
- Step Pharma — Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe.
- Biodol Therapeutics — Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key player for triggering and maintaining the chronic neuropathic pain (NP) state. New findings from Biodol Therapeutics' academic partnership (CyrilRivat and Jean Valmier at the INSERM Institute for Neurosciences in Montpellier) also demonstrated that FLT3 inhibition increases the potency of opioids for their analgesic effect, and hereby reduces their safety risks, especially addiction risk, which will help fighting the Opioid Crisis. The development of extracellular inhibitors of the FLT3 receptor, is a proprietary and key approach developed by Biodol Therapeutics.
Capricorn Partners is a unique independent manager of venture capital, growth capital and quoted equity funds
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series A, Series B
- Geography: Belgium, The Netherlands, United States
Investor stats
- Total investments: 120
- Round size: Series A $3.3M–$18M; Series B $5.3M–$42M
- Lead/follow: 33% lead, 67% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Sensolus — Sensolus provides care-free tracking of your valuable non-powered assets directly from the cloud.Sensolus offers turnkey solutions for wireless, low-power context-aware sensing. Sensolus developed a personal product line of low-power tracker systems called STICKNTRACK.Sensolus is built upon many years of expertise in low-power networks,wireless sensor design, cloud-based sensor management, analytics, and applications.
- Endo Tools Therapeutics — Endo Tools Therapeutics is dedicated to the development of innovative devices that provide therapeutic interventions for gastric conditions
- Delft Advanced Biorenewables — We enable the bio-economy by improving the productivity of fermentations with our in-situ product recovery (ISPR) technology.
The Qbic Fund is a multi-sector fund supporting spin-off companies of the Ghent, Brussels and Antwerp university associations and of VITO. Through its strategic partnership with the universities of Ghent, Brussels and Antwerp, and VITO, the Qbic Fund has early and privileged access to promising research projects at these partner universities. Ourinvestment approach is based on early in-depth and independent review and analysis followed by hands on involvement and support.In May 2012 the Qbic Fund held its first close and currently it has over € 30 million under management. The Qbic Fund is backed by several public and private investors and managed by Qbic Venture Partners.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Seed, Series A
- Geography: Belgium, The Netherlands
Investor stats
- Total investments: 61
- Round size: Seed $1.3M–$7.4M; Series A $906k–$28M
- Lead/follow: 31% lead, 69% follow
- Last fund: Likely still investing — raised $57M in 2022
Portfolio highlights
- Firecell — Firecell is a Telecommunications Industry.
- Eyeo — eyeo revolutionizes imaging with color splitter sensors. Capture sharper, brighter images in low light using optical waveguide innovation, discover how it works
- Sightera Biosciences — Revolutionizing drug discovery through AI-powered analysis of patient-derived models for breakthrough therapeutics in cancer and regenerative medicine.
Vives is an interregional seed and early stage technology multi-sector fund. The new fund, initiated by UCLouvain, is a unique European inter-university fund having access to world class innovations from leading EU top universities.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Seed
- Geography: Belgium, France, United States
Investor stats
- Total investments: 27
- Round size: Seed $1.6M–$7.3M; Series A $491k–$46M; Series B $4.7M–$125M
- Lead/follow: 4% lead, 96% follow
- Last fund: May invest from a new fund soon — raised $37M in 2020
Portfolio highlights
- BOTALYS — BOTALYS uses an innovative Biomimetic Indoor Farming technology to recreate the ideal wild conditions for rare botanicals to grow in. We develop pristine & potent botanical ingredients for the Nutraceutical and Cosmetic industries.
- Sunrise — Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
Strategic research in on life sciences and biotechnology
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: Belgium, Brazil, Denmark
Investor stats
- Total investments: 27
- Round size: Seed $3.1M–$11M; Series A $6.8M–$84M; Series B $4.7M–$65M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Biotalys — Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combinethe high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium.
- MRM Health NV — MRM Health NV, is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome. MRM Health was incorporated early 2020 by MRM Technologies, a Center of Expertise for microbiome research based in the biotech cluster in Ghent, in a joint venture with the Flemish Institute ofBiotechnology (VIB), an excellence-based entrepreneurial life sciences research institute in Flanders, Belgium, that focuses on translating basic scientific results into pharmaceutical, agricultural and industrial applications.
- Rainbow Crops — Rainbow Crops is a next-generation Agtech company developing climate-resilient, high-performing crop varieties.
W.IN.G by Digital Wallonia invests in SAAS, advanced tech and deep tech startups (AI, drones, medtech, IOT,...). W.IN.G brings smart money by helping startups by bi-weekly interactions and providing an operating teams (seasonal entrepreneurs being hands-on with the portfolio).
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Series A, Convertible Note
- Geography: Belgium
Investor stats
- Total investments: 34
- Round size: Seed $346k–$1.9M; Series A $1.1M–$11M; Convertible Note $219k–$555k
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- IONNYK — IONNYK is a new medium of art photography, containing millions of tiny ink capsules.
- MYOCENE — Myocene is a Liège-based sports technology company which creates unique and innovative devices for measuring muscle fatigue and performance.
- Soil Capital Belgium — Discover Europe's first certified, multi-national carbon farming programme that rewards regenerative agriculture.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Our mission is to mature innovation and support the growth of our portfolio companies to create value for patients, society, local ecosystems, and investors.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Seed
- Geography: Belgium, Japan, France
Investor stats
- Total investments: 22
- Round size: Seed $2.7M–$3.2M; Series A $6.1M–$84M
- Lead/follow: 68% lead, 32% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Bioxodes — Bioxodes is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics to prevent thrombotic events without hemorrhagic risk.
- Tensegrity Pharma — Tensegrity Pharma is the developer of a novel drug designed to minimize bottlenecks and provide innovative value to patients.
- Augustine Therapeutics — Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular, neurodegenerative and cardiometabolic diseases. Discover our pipeline poised for clinical impact.
Oxygen for growth - LRM
Show more...Investment focus
- Industry: Information Technology, Software, Biotechnology
- Stage:Seed, Series A
- Geography: Belgium, The Netherlands, United States
Investor stats
- Total investments: 97
- Round size: Seed $494k–$5.2M; Series A $1.6M–$11M
- Lead/follow: 12% lead, 88% follow
Portfolio highlights
- Monsana — Monsana's AI-powered platform empowers both patients and healthcare professionals in their search for the perfect clinical trial. Each eligibility criterion is validated based on your unstructured textual medical records, allowing highly accurate matching with experimental treatments.
- ADLC — ADLC employs drone technology to deliver logistics services, allowing businesses to implement drone-based solutions without having to manage them in-house. The company is focused on enhancing last-mile delivery in maritime and offshore environments. ADLC now conducts drone delivery services in the Port of Antwerp in collaboration with SGS, atesting and certification company, and works with companies such as BASF. Its drones have reduced delivery times and environmental effect, boosting efficiency sixfold and lowering CO2 emissions by up to 80% for petrochemical sample deliveries.
- Optiflux — Optiflux automatiseert het bewaarbeheer van vers fruit met slimme AI & vision-technologie. Minder verlies, meer winst voor teler & handelaar.
Sambrinvest is an active venture capital player in the region of Charleroi - Thuin.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: Belgium, France, Spain
Investor stats
- Total investments: 40
- Round size: Seed $544k–$24M; Series A $987k–$46M; Series B $4.4M–$45M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Brenus Pharma — Brenus Pharma is an allogeneic platform to generate immune therapy ambitioning to harness patient immune system & prevent cancer resistance over treatment.
- Vertical Compute — Vertical Compute offers chiplet-based technology that cuts data movement to achieve up to 80% energy savings.
- Enodia Therapeutics — Enodia Therapeutics pioneers targeted protein degradation at the Sec61 translocon, developing small-molecule therapies for inflammatory and autoimmune diseases.
For game changers in medtech
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Belgium, United States
Investor stats
- Total investments: 12
- Round size: Seed $4.1M–$11M; Series A $5.3M–$12M; Venture - Series Unknown $5.5M–$11M
- Lead/follow: 67% lead, 33% follow
- Last fund: May invest from a new fund soon — raised $23M in 2019
Portfolio highlights
- neuroClues — An easy-to-use eye-tracking environment to help practitioners instantaneously quantify their clinical exam
- Minze Health — Minze Health is a health tech start-up that builds creative digital health solutions for urology, pelvic health, and (in)continence care.
- Clouds of care — Increasing your probability of success through the adoption of meaningful endpoints, starting from electrophysiology.
Inventures is a European venture capital fund that builds a better world through a portfolio of investments in sustainable businesses.The firm has two funds: Inventures I & Inventures II.Inventures was created to support early stage smart and innovative European businesses, to support sustainable job growth and empower entrepreneurs.Inventures empowers citizenship co-investments through a crowdfunding platform, MyMicroInvest.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Manufacturing
- Stage:Series A, Seed
- Geography: Belgium, France, United Kingdom
Investor stats
- Total investments: 46
- Round size: Seed $82k–$2.1M; Series A $411k–$14M
- Lead/follow: 9% lead, 91% follow
- Last fund: May invest from a new fund soon — last raise in 2016
Portfolio highlights
- BiOceanOr — BiOceanOr harnessed the power of Marine Biology and AI to deliver bio-guided services that optimize fish welfare and fish growth, while supporting aquaculture sustainability standards
- myskillcamp — Myskillcamp is a digital learning platform and educational design support service. Myskillcamp supports their customers in the digital transformation of their company and the launch of their Digital Learning project. From the audit of needs to the design of engaging educational devices, through a pilot phase, they make a point of honor to adapt thedigital to the specificities of each and give it meaning.With their online platform, businesses can manage their learner communities and connect all their partners in one place. Their tool also allows businesses to structure training spaces by skills, trades, brands within camps. In parallel, businesses can create educational content from scratch, select a map in their marketplace, or plan sessions in-class. Businesses can organize the distribution of their training to a single learner or to a whole group.
- Octave — Optimize energy use with Octave's battery storage (BESS) and energy management system (EMS). Reduce costs, increase flexibility.
KBC Private Equity - the investment company of KBC Group - provides development capital and finances buy-outs to medium-sized companies in Belgium and in Central and Eastern Europe, KBC's home markets.Boasting an experienced team of 28 people, it has more than 60 active investments in portfolio with a market value in excess of EUR 400million.KBC Private Equity aims to become one of the leading private equity providers on KBC Group's home markets. As an active shareholder with a long-term perspective, KBC Private Equity is involved in taking strategic decisions and providing support to management teams.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A, Pre-Seed
- Geography: Belgium, United States, The Netherlands
Investor stats
- Total investments: 36
- Round size: Seed $549k–$8M; Pre-Seed $425k–$1.9M; Series A $3M–$65M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Rookoo — Rookoo is AI-powered venue management software that automates event inquiries, checks availability, and books events 24/7. Used by Clays, Tour & Taxis, Wintercircus and more.
- Qivalis — Qivalis is a financial technology company designed for payments, settlements, and financial services.
- Ion Beam Applications — Ion Beam Applications is a Belgium-based company that develops and markets technologies, pharmaceutical products and tailored solutions for the healthcare sector, with emphasis on cancer diagnosis and therapy. IBA is also active in the sterilization and ionization field. The Company operates through two business segments, namely the pharmaceuticalssegment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry.
Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, The Netherlands, Switzerland
Investor stats
- Total investments: 184
- Round size: Series A $7.3M–$78M; Series B $12M–$110M; Series C $12M–$165M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $266M in 2023
Portfolio highlights
- ActoGeniX — ActoGeniX is a biopharmaceutical company focused on the development and commercialization of a range of biological drugs. ActoGeniX was founded by Bernard Coulie and Mark Vaeck in 2006 and is based in Zwijnaarde, Belgium.
- Neurent Medical — Discover NEUROMARK, a minimally invasive solution for Chronic Rhinitis that targets the posterior nasal nerve to provide lasting symptom relief.
- Rotation Medical — Rotation Medical Inc. manufactures and markets a collagen scaffold for rotational cuff disease in Minnesota. The company was formerly known as Denali Medical Inc. and changed its name to Rotation Medical Inc. in March 2010. Rotation Medical was founded in 2009 and headquartered in Plymouth, Minnesota.
Vesalius Biocapital Partners invests in companies active in human health through venture capital funds raised since 2007. They have contributed to developing 20 companies since inception.With more than € 150 million under management in two funds. Vesalius Biocapital Partners plays the role of lead investor in the large majority of its financingrounds.Their companies are based in Europe allowing easy interaction with management.They invest in all stages of development and do not shy away from relatively early-stage projects with a sound proprietary technology and corresponding IP, unique team skills and a clear competitive edge based on solid data.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Belgium, Germany, France
Investor stats
- Total investments: 61
- Round size: Series A $3.9M–$20M; Series B $4.4M–$25M; Series C $7M–$100M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Nutrium — Nutrium is the most up-to-date nutrition software for dietitians and nutritionists to manage their nutrition business with nutritional assessment, meal planning and progress tracking.
- ENYO Pharma — ENYO Pharma is a biopharmaceutical company incorporated in Jan, 2014, by four scientists of the Infectiology Research Center in Lyon, France, and three seeding partners (2 privates and 1 public).The company is based in the Infectiology Center of Lyonbiopôle in Lyon, France and maintains tight collaborations with the seminal Inserm team and theBSL4 laboratory Inserm-Jean Mérieux.ENYO Pharma has licensed several Inserm patents issued from the discoveries of the founding scientists and developed a unique platform for the identification of intracellular therapeutic targets and molecules.The company is developing treatments against the most important viruses and is thriving to become a global leader in anti-virals. Research and Development is currently focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company plans to conduct its molecules to Phase II clinical trials.
- Inflammatix — Inflammatix develops rapid point of care diagnostic tests by reading the immune system, and resolves major clinical health challenges.
Gimv, a trusted European investment company, helps mid-market businesses create sustainable value through growth capital and expertise across diverse sectors.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: Belgium, United States, France
Investor stats
- Total investments: 171
- Round size: Series A $3.3M–$79M; Series B $8.8M–$73M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $622M in 2010
Portfolio highlights
- spineart — Spineart is a privately held medical device company focused on simplifying the surgical act by designing, developing and promoting safe and efficient solutions to spine surgeons, operating room teams, and patients.
- NovoPolymers — NovoPolymers NV is a company, with the vision and mission to develop and produce sustainable solutions for primarily the photovoltaic market.
- Kinaset Therapeutics — Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts.
Spinventure supports the creation of spin-off companies that aim to industrialize and commercialize the result of scientific research. Spinventure was born from a collaboration between MEUSINVEST and the University of Liège. It is headquartered in Angleur, Belgium.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A
- Geography: Belgium
Investor stats
- Total investments: 6
- Round size: Series A $768k–$15M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Dim3 — Improve patients outcome - Deliver actionable insights - Save healthcare costs
- Elysia — Elysia developed solution dedicated to quality control laboratories for the production of Radio Pharmaceuticals.
- Convert Pharmaceuticals — Convert Pharmaceuticals develops prodrugs that are inert upon administration to patients, but transform into potent anti-cancer agents upon entering tumors.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Early-stage venture capital fund focused on alumni of the imec.istart accelerator and exceptional tech founders building in Applied AI, Spacetech, Healthtech, and Deep Tech. Based in Antwerp, Belgium.
Show more...Investment focus
- Industry: Health Care, Medical Device, Satellite Communication
- Stage:Seed, Pre-Seed, Series A
- Geography: Belgium, United Kingdom
Investor stats
- Total investments: 10
- Round size: Seed $1.2M–$5.7M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- EDGX — EDGX, founded in 2023 in Ghent, is a Belgian Space Tech company developing high-speed edge computing units for satellites. Its NVIDIA-powered Sterna Computer and SpaceFeather software enable real-time, AI-driven on-orbit data processing for applications in communication, Earth observation, and intelligence.
- nxgsat — We build interoperable satellite networks.
- OnTracx — OnTracx measures and manages the load your body experiences, step by step. Our sensor captures real-time load during any run, bringing lab-level precision to real-world conditions. The app empowers runners to monitor their progress, while OnTracx Pro gives professionals the tools for load screenings, training program creation, and effortless athlete follow-up.
SFPIM investment firm that invests in technology and infrastructure.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Semiconductor
- Stage:Series A, Venture - Series Unknown
- Geography: Belgium, France, Switzerland
Investor stats
- Total investments: 26
- Round size: Series A $8.6M–$57M; Venture - Series Unknown $11M–$251M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- D-CRBN — D-CRBN recycles CO2 for industrials through our patented CCU plasma technology. We use plasma to convert CO2 emissions to useful chemical building blocks. Our plasma process splits CO2 molecules into their original building blocks to make e-fuels, chemicals, or polymers to ultimately achieve a circular and more sustainable economy. Battling global warming will be the toughest environmental challenge that our society has ever faced. We have set our objectives to help reduce CO2 emissions, reaching a carbon-neutral society by 2050. Launch your CO2 recycling initiative at your plant, go net-zero and join us to Sparc* the new industrial revolution.
- e-peas — Discover e-peas, pioneer of the Ambient IoT concept since 2014, which offers the most efficient energy harvesting pmics on the market to make your devices more energy self-sufficient: AEMs.
- Biotalys — Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combinethe high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium.
Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Germany, Switzerland
Investor stats
- Total investments: 104
- Round size: Seed $1.8M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — raised $250M in 2018
Portfolio highlights
- Tacalyx — Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms.
- smartbax — We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
- Rinri Therapeutics — Rinri Therapeutics has been founded on pioneering research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield.
HERAN PARTNERS is a Belgian-based investment fund founded by Annie Vereecken together with Katleen Vandersmissen, Joris Mortelmans and Herman Verrelst within the sector of MedTech and Digital Health. With a clear focus on European HealthTech, the fund provides venture & growth capital accompanied by a strong network, expertise and mentorship tostartups and scale-ups with a strong technology platform and market potential.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Hospital
- Stage:Series A, Seed
- Geography: United Kingdom, Belgium, The Netherlands
Investor stats
- Total investments: 12
- Round size: Seed $2M–$8.1M; Series A $12M–$23M
- Lead/follow: 42% lead, 58% follow
Portfolio highlights
- Pharmacelera — Improving pharmaceutical R+D productivity through a lean drug discovery process based on advanced computational methodologies.
- Hypervision Surgical — Making surgeries more precise, safer and faster. Guiding the future of surgery using AI-powered hyperspectral imaging.
- Broken String Biosciences — The next generation of genome-wide on- and off-target analysis in your own hands. Our INDUCE-seq platform provides precise off-target detection and genome-wide insights.
Droia Ventures is a specialist investor, dedicated to making an impact and save patient lives. We invest in the most promising life science companies.
Show more...Investment focus
- Industry: Biotechnology, Medical, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Belgium, The Netherlands
Investor stats
- Total investments: 40
- Round size: Series A $12M–$75M; Series B $29M–$89M; Series C $75M–$125M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — raised $241M in 2021
Portfolio highlights
- Actio Biosciences — Actio Biosciences involves in the development of precision medicines for homogenous rare patient populations. They develop a pipeline of new medicines with the goal to enhance the probability of clinical success and deliver medicines for all patients.
- Protego Biopharma — Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California.
- Unnatural Products — Unnatural Products is a startup pairing AI with chemistry to create treatments for drug targets. Its AI-enhanced technology platform creates entirely new drugs by engineering passively permeable, macrocyclic peptides that access traditionally undruggable targets.Unnatural Products was founded in 2017 and is headquartered in Santa Cruz,California.
Omnes Capital takes a unique approach to renewable energy, transforming developers into independent power producers to provide green energy to millions.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Series A, Series B
- Geography: France, Germany, United States
Investor stats
- Total investments: 184
- Round size: Series A $3.5M–$41M; Series B $4.4M–$53M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $403M in 2020
Portfolio highlights
- VSORA — VSORA provides high performance companion solutions combining AI and signal processing to enable autonomous driving and ADAS
- SeqOne Genomics — Healthcare is undergoing a revolution, known as genomic medicine, that uses the patient’s genomic information to optimise treatment. This trend is accelerating thanks to the arrival of New Generation Sequencing (NGS) techniques that have reduced the cost of decoding genomic material while increasing the amount useful data obtained. However, NGShas had only limited impact on mainstream healthcare due to the difficulties in analyzing more and richer genomic data. SeqOne’s mission is to provide tools that enable the healthcare industry to analyse NGS genomic data better and more cost-effectively to provide universal access to genomic medicine.
- Complix — Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
Mérieux Equity Partners (“MxEP”) is a management company dedicated to venture, growth and LBO investments in the healthcare and nutrition sectors. MxEP actively supports entrepreneurs and industrial companies with differentiated products and services, by providing privileged access to its expertise and international network. MxEP currently managesmore than €600m AUM and has recently launched a new vehicle MP3 of €350m dedicated to growth/LBO.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Private Equity
- Geography: France, United States, Belgium
Investor stats
- Total investments: 57
- Round size: Series A $5.7M–$23M; Private Equity $22M–$150M
- Lead/follow: 37% lead, 63% follow
- Last fund: May invest from a new fund soon — raised $417M in 2020
Portfolio highlights
- DeepUll — DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise.
- Ceva Santé Animale — Ceva Sante Animale S.A. engages in the research, development, production, and marketing of pharmaceutical products and vaccines for companion and farm animals. They work with welfare and social programmes around the world to bring this vision to life – anywhere their products and know-how can make a difference and with all kinds of partners. FromUganda, working with small-scale livestock owners and vets to stop sleeping sickness in its tracks, to the UK and USA, where they supply the biggest animal welfare charities with Adaptil® collars to help re-home shelter dogs.
- CorFlow Therapeutics — CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complicationrates in these patients.
Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Seed, Series B
- Geography: France, Switzerland, Spain
Investor stats
- Total investments: 142
- Round size: Seed $2.7M–$14M; Series A $3.8M–$98M; Series B $12M–$72M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- EvlaBio — EvlaBio is a biotech company focused on the development of drug programs that address significant unmet medical needs. The company's pipeline includes robust scientific antibody programs for the treatment of hepatocellular carcinoma (Phase 1 ready) and chronic kidney disease with left ventricular hypertrophy (pre-clinical).
- Tacalyx — Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms.
- AM Pharma — AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
Fund+ is a venture capital firm that invests in companies operating in the diagnostics, therapeutics, medical devices, and life science sectors. The firm wants to create sustainable shareholders' value, contribute to the development of a leadership position in the life sciences sector, and generate a tangible, beneficial societal impact.Fund+ was established in 2015 and is based in Leuven, Belgium.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: Belgium, United States, Spain
Investor stats
- Total investments: 32
- Round size: Series A $11M–$46M; Series B $22M–$125M; Series C $11M–$401M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Ona Therapeutics — Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
New Science Ventures is a venture capital firm that focuses on investments in life sciences and information technology companies. They invest in early and late stage companies taking novel scientific approaches to address significant unmet needs, while creating order-of-magnitude improvements in performances. The company also invests in companiesusing science-based innovations to address market needs in life sciences such as pharmaceuticals, biologics, medical devices, diagnostics, and IT. The team of the company expertise in strategy and corporate planning, operations and cost management, and leadership development.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series D
- Geography: United States, United Kingdom, Belgium
Investor stats
- Total investments: 87
- Round size: Series A $4M–$49M; Series B $8M–$52M; Series D $5M–$38M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — raised $4.9M in 2020
Portfolio highlights
- EXTEN Technologies — EXTEN HyperDynamic software platform solves the primary challenges of today's data centers: the necessity of keeping up with surging data density, velocity, and volume requirements, and the need for increased application agility.
- BrightVolt — BrightVolt is an innovative manufacturer of solid-state thin & flexible lithium polymer batteries and power-efficient thin & flexible microelectronics for IoT clients. It specializes in the fields of battery, electronics, and manufacturing. BrightVolt got recapitalization in November 13, 2013.
- Trellis Bioscience — Trellis Bioscience develops a technology platform for cellular informatics. The company's technology has applications in the discovery and production of therapeutic monoclonal antibodies. Its cell biology platform provides a direct readout at the single cell level for monitoring activity of diverse cell types and quantifying the impact ofpotential therapeutic interventions. The company is based in San Francisco, California.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!AdBio partners is a European Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward.We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and driveinventive Life Sciences start-ups to success.We embrace European Life Sciences’ dynamic of innovation. Europe harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. AdBio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring Europe’s biotechnology ecosystem.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: France, Spain, Belgium
Investor stats
- Total investments: 32
- Round size: Seed $2.2M–$18M; Series A $18M–$37M; Venture - Series Unknown $2.2M–$16M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $116M in 2021
Portfolio highlights
- Orikine Bio — Orikine Bio is a pioneer biotech company in the field of tailored cytokines with unmatched biological properties for the treatment of immune-mediated disorders.
- ARTHEx Biotech — ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing advanced RNA treatments against genetic diseases.
- Integra Therapeutics — Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases.
WE International is a financial firm that provides an array of loans, funding, acquisition, and investment services.
Show more...Investment focus
- Industry: Health Care, Energy, Biotechnology
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Belgium, United States, France
Investor stats
- Total investments: 23
- Round size: Seed $2.2M–$43M; Series A $10M–$57M; Venture - Series Unknown $16M–$251M
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- e-peas — Discover e-peas, pioneer of the Ambient IoT concept since 2014, which offers the most efficient energy harvesting pmics on the market to make your devices more energy self-sufficient: AEMs.
- neuroClues — An easy-to-use eye-tracking environment to help practitioners instantaneously quantify their clinical exam
- VolitionRx — We are dedicated to revolutionizing the diagnosis and monitoring of life-altering diseases by advancing the science of epigenetics.
TheClubDeal is an investment holding and fund manager co-investing into SME’s and real estate projects. It provides facilitation of governance between non-executive shareholders and entrepreneurs. Its governance structure, including its charter of avoidance of conflict of interests, is therefore paramount to the adequate management of the Company.At TheClubDeal, we connect Investors and Entrepreneurs around promising investment opportunities. For each of these, we will invest ourselves and co-invest with a selected number of investors. We add value by processing strong applied governance principles, when selecting and managing our investments, and by gathering the necessary skills to successfully grow the businesses and real-estate projects we co-invest in. TheClubDeal is launching their second fund, a 50M € PRIVAK/PRICAF in H1 2021 with the mandate to invest in Belgian scale-ups in three sectors: Smart Living, Tech and Life Sciences.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical Device
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: Belgium, France
Investor stats
- Total investments: 18
- Round size: Series A $2.1M–$7.7M; Series B $13M–$18M; Venture - Series Unknown $5.5M–$6.5M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Vaxinano — Vaxinano is a biotechnology company specialized in preclinical and pharmaceutical development of human and veterinary vaccines and drug delivery systems. Vaxinano was created in 2016, building on 25 years of research and clinical trials on vaccines and the patented technology of Pr Didier Betbeder.
- Inpulse — Inpulse is an automated supply management platform for restaurateurs.
- Clouds of care — Increasing your probability of success through the adoption of meaningful endpoints, starting from electrophysiology.
Volta Ventures backs ambitious B2B software founders in the Benelux with early-stage capital, strategic guidance and long-term support.
Show more...Investment focus
- Industry: Software, Information Technology, SaaS
- Stage:Seed, Series A, Pre-Seed
- Geography: Belgium, The Netherlands, United States
Investor stats
- Total investments: 91
- Round size: Seed $850k–$5.2M; Pre-Seed $1M–$3M; Series A $2.2M–$10M
- Lead/follow: 49% lead, 51% follow
- Last fund: May invest from a new fund soon — raised $72M in 2019
Portfolio highlights
- Kyvvu — Kyvvu is an Agent Security Kernel (ASK): an in-process security layer that checks every action an AI agent takes — against the full path of the task so far — and allows, warns, or blocks it before it runs, deterministically, in under a millisecond, without your data ever leaving your environment.
- Nodalview — Nodalview helps real estate agents deliver cutting edge content and an impressive buying experience for happy and loyal customers.
- CHILI publish — Allow users to edit customizable documents, or fully automate artwork generation. Output files are ready to use for print and digital.
B2venture is a venture capital firm focused on early-stage investments in digital and industrial technology companies. B2venture invests EUR 100m+ per year in high-growth companies with ticket sizes from EUR 0.25m to 3.5m.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Series A, Seed, Series B
- Geography: Germany, Switzerland, United Kingdom
Investor stats
- Total investments: 244
- Round size: Seed $1.3M–$9M; Series A $4M–$24M; Series B $8.3M–$52M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — raised $135M in 2021
Portfolio highlights
- Everlab — The preventative health service of the future. Detect disease early, improve wellbeing, and optimise performance.
- Flyboard — Human-level AI voice agents at a fraction of the cost. Transform your customer engagement with intelligent automation.
- Kiin Bio — Drug discovery is a system problem, where every inefficiency amplifies the next. We have the solution.
Shaping new life-science ventures.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Health Care
- Stage:Series A, Seed
- Geography: The Netherlands, United States, Belgium
Investor stats
- Total investments: 65
- Round size: Seed $1.1M–$50M; Series A $5.3M–$86M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $148M in 2021
Portfolio highlights
- Dualyx — Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.
- Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
- Noviogendix Holding — NovioGendix, a privately-held molecular diagnostics company focused on the development of a non-invasive liquid biopsy test for prostate cancer. NovioGendix, based in Nijmegen (The Netherlands), is a molecular diagnostic company providing an expert-based, integrated approach in developing advanced and clinically useful molecular diagnosticassays for uro-oncological practice. NovioGendix has a range of diagnostic tests for prostate, bladder, kidney and other urologic cancers in various stages of development. Commencing activities in 2008 as a Radboud University Medical Center (Radboudumc) spin-off company, NovioGendix has a standing cooperation with various Radboudumc departments. The main shareholders of NovioGendix include BioGeneration Ventures, and Participatiemaatschappij Oost Nederland.
Theodorus is the spin-off fund of Université Libre de Bruxelles that invests ininvest in early stage projects based on proprietary disruptive technologies.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Life Science
- Stage:Series A, Seed
- Geography: Belgium, Canada, France
Investor stats
- Total investments: 17
- Round size: Seed $3.7M–$18M; Series A $2.2M–$41M
- Lead/follow: 24% lead, 76% follow
Portfolio highlights
- Simmunome AI — We use AI to create accurate, comprehensive disease models using multi-omic data to determine the probability of success of a drug. Our clinical trial simulations allow you to gain insights, make go/no-go decisions, and de-risk your pipeline, getting you to market faster and reducing your R&D co
- Flare — Flare equips your team to shut down cybercrime before it escalates. Detect, prioritize, and remediate external cyber threats with automated Threat Exposure Management.
- Ability biologics — Ability develops innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases.
We empower high-potential entrepreneurship and democratize venture capital. Discover promising start-ups & SMEs and invest alongside business angels.
Show more...Investment focus
- Industry: Information Technology, E-Commerce, Health Care
- Stage:Series A, Seed, Pre-Seed
- Geography: Belgium, France
Investor stats
- Total investments: 16
- Round size: Seed $165k–$1.3M; Pre-Seed $150k–$197k; Series A $247k–$2.5M
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- Jelloow — Jelloow your virtual marketing navigator. Matching brands with likeminded marketing agencies.
- PlayTreks — Supercharge your music business with PlayTreks, the all-in-one workspace for music professionals. Built for indie artists, artist managers and label teams.
- NietsCo — NietsCo. is the home of Botaniets Gin 0.0%, a leading selection of alcohol-free products, carefully distributed to the world's best restaurants, concept stores, shops and consumers.
Early stage Entrepreneurs Coaching and FinancingOne of Europe's leading Business Angels Networks. We connect innovative growth companies to equity finance and coaching by experienced angel investors. The network is 250 members strong and has been assisting innovative entrepreneurs to find financing for more than 10 millions Euros in thelast 4 years.
Show more...Investment focus
- Industry: SaaS, Software, Information Technology
- Stage:Seed, Pre-Seed
- Geography: Belgium, France, Luxembourg
Investor stats
- Total investments: 25
- Round size: Seed $247k–$1.5M; Pre-Seed $78k–$571k
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- ChainComply — ChainComply provides enhanced KYT due diligence solutions for banks and VASPs and relieves them from stressing over incoming transfers from crypto exchanges. ChainComply develops a SaaS tool that scans the client's crypto exchange and blockchain transaction history to reveal the source of funds of crypto holders. The company solutionsimplifies complex transaction streams, and then it identifies high-risk transactions and patterns, enabling AML teams to understand their clients better and meet regulatory obligations efficiently.
- Visiblie — Track and optimize your brand across ChatGPT, Claude, Gemini, and Perplexity. Monitor AI mentions, analyze competitors, and grow AI search visibility.
- TalentGuide — Unlock workforce potential with Talentguide's skills intelligence platform, transforming ambition into measurable ability through actionable insights and personalized development paths.
Impacting the future of medicine.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 208
- Round size: Series A $19M–$180M; Series B $16M–$155M; Series C $19M–$120M
- Lead/follow: 52% lead, 48% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
- Inflazome — Situs gacor premium Megawin188 paling banyak di minati oleh semua kalangan karena pecah selayar tanpa henti dan memiliki tampilan yang sangat memanjakan mata.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 370
- Round size: Series A $9.9M–$133M; Series B $12M–$135M; Series C $30M–$118M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- Tarveda Therapeutics — Developing Pentarins to make a difference in the treatment of patients with solid tumor malignancies
- Tarsa Therapeutics — Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that slows the rate of bone destruction.
- Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
Ackermans & van Haaren is a diversified group active in 5 segments: Marine Engineering & Infrastructure; Private Banking; Real Estate, Leisure & Senior Care; Energy & Resources; Development Capital. Marine Engineering & Infrastructure: DEME, one of the largest dredging companies in the world - Algemene Aannemingen Van Laere,a leading contractor in Belgium. Ackermans & van Haaren is an independent and diversified group aiming at creating shareholder value through long-term investments in a limited number of companies with growth potential on an international level.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series B, Seed, Series A
- Geography: Belgium, India, Germany
Investor stats
- Total investments: 18
- Round size: Seed $30M–$42M; Series A $8.4M–$15M; Series B $3.4M–$72M
- Lead/follow: 39% lead, 61% follow
Portfolio highlights
- Biotalys — Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combinethe high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium.
- MRM Health NV — MRM Health NV, is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome. MRM Health was incorporated early 2020 by MRM Technologies, a Center of Expertise for microbiome research based in the biotech cluster in Ghent, in a joint venture with the Flemish Institute ofBiotechnology (VIB), an excellence-based entrepreneurial life sciences research institute in Flanders, Belgium, that focuses on translating basic scientific results into pharmaceutical, agricultural and industrial applications.
- DISCO Pharmaceuticals — DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.
Miles Ahead is a Venture Studio that helps first-time founders of Deep Tech & AI startups to grow faster by producing and funding their business within an empowering environment.
Show more...Investment focus
- Industry: Software, Big Data, Robotics
- Stage:Seed, Pre-Seed
- Geography: Belgium, Ireland, United Kingdom
Investor stats
- Total investments: 11
- Round size: Seed $1M–$3.3M; Pre-Seed $1.1M–$2.3M
- Lead/follow: 64% lead, 36% follow
Portfolio highlights
- OTIV — OTIV offers autonomous technology to make your railway operations in complex environment safer and more efficient.
- DevAlly — AI-powered accessibility compliance for product teams who ship fast
- TalentGuide — Unlock workforce potential with Talentguide's skills intelligence platform, transforming ambition into measurable ability through actionable insights and personalized development paths.
Qbic is the result of a lot of thinking, debating and sketching of what a city hotel could be; one that breaks the rules and makes people smile.An astonishing level of change has swept through the world over the last few years. But the hotel experience is no different than it’s ever been: stuffy, over-priced and lacking soul. They’re here tochange all that. they’re curious, imaginative and friendly, and they think there are lots of people just like us seeking a hotel with personality in the middle of the city.They believe in something better than what’s currently out there. A place that celebrates life rather than sucks life out of it. A hotel that’s built on creativity and a belief that you don’t have to accept the conventional. Somewhere that sends you away with fun stories and ideas, and is easy on your pocket.
Show more...Investment focus
- Industry: Health Care, Biotechnology, AgTech
- Stage:Seed, Series B
- Geography: Belgium
Investor stats
- Total investments: 7
- Round size: Seed $3.7M–$11M; Series B $8.2M–$12M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- moveUP — Ontvang medische zorg op afstand voor en na uw operatie. moveUP is gespecialiseerd in de begeleiding van knie- en heupoperaties.
- Axithra — Axithra provides therapeutic medication monitoring and measures beta-lactam antibiotic concentrations in blood.
- Cascador Health — Cascador Health bridges the gap between sources and users of healthcare data. Using curated, validated and anonymized RWD allows healthcare providers and life science industry to gain insights and provide better care.
Buysse and Partners is a private equity investment group based in Antwerpen that offers smart equity, a growth fund, and partnerships.
Show more...Investment focus
- Industry: Software, Cloud Computing, FinTech
- Stage:Series A, Seed, Venture - Series Unknown
- Geography: Belgium, United Kingdom, The Netherlands
Investor stats
- Total investments: 6
- Round size: Seed $1.1M–$2M; Series A $3.9M–$11M
- Lead/follow: 50% lead, 50% follow
- Last fund: May invest from a new fund soon — raised $23M in 2012
Portfolio highlights
- Twikit — Deliver unforgettable customer experiences with real time 3D product configurators, linked to your existing order and manufacturing flows.
- Bluebee — Delivering a streamlined way for users to analyze, explore, and manage large-scale genomics data in the cloud.
- moonbird — Hold moonbird in your hand and breathe along. A tactile, screen-free breathing coach trusted by 80,000+ users for less stress, better sleep, and more calm.
Fountain Healthcare Partners is an Irish based life science venture capital fund. Fountain is exclusively focused on the life science sector. Specific areas of interest to them are: specialty pharma, medical devices, biotechnology and diagnostics. They will deploy the majority of their capital in Europe with a strong focus on Ireland.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Series C
- Geography: Ireland, United States, France
Investor stats
- Total investments: 50
- Round size: Series A $6.3M–$43M; Series B $5.5M–$68M; Series C $3.3M–$110M
- Lead/follow: 42% lead, 58% follow
- Last fund: May invest from a new fund soon — raised $128M in 2019
Portfolio highlights
- Palyon Medical — Palyon Medical Corporation is a medical device company developing technologies for the treatment of chronic pain, spasticity and other neurological diseases.
- Neuromod Devices — Neuromod is the global medical device company that developed Lenire, the FDA Approved tinnitus treatment device.
- Vivasure Medical — Pioneering the Future of Large-Bore Vessel Closure for Arterial and Venous Access. The first and only 100% bio-absorbable, sutureless patch..
Namur Invest Group provides companies with financing solutions in various forms adapted to their needs, to strengthen their financial.
Show more...Investment focus
- Industry: Health Care, Medical Device, Auctions
- Stage:Series A, Seed
- Geography: Belgium, United States
Investor stats
- Total investments: 8
- Round size: Series A $658k–$18M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Invineo — Invineo design and development of a "smart machine" for catering and hospitality professionals.
- VolitionRx — We are dedicated to revolutionizing the diagnosis and monitoring of life-altering diseases by advancing the science of epigenetics.
- Sunrise — Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
Expanding nanotechnology into business.
Show more...Investment focus
- Industry: Semiconductor, Manufacturing, Medical Device
- Stage:Seed, Series A, Series B
- Geography: Belgium, United States, Germany
Investor stats
- Total investments: 54
- Round size: Seed $3.3M–$23M; Series A $8.7M–$56M; Series B $12M–$100M
- Lead/follow: 48% lead, 52% follow
- Last fund: Likely still investing — raised $351M in 2024
Portfolio highlights
- Invisix — Invisix shrinks the metrology wavelength with soft x-ray light to measure next-gen 3D chips and extend Moore's law for semiconductor makers.
- Eyeo — eyeo revolutionizes imaging with color splitter sensors. Capture sharper, brighter images in low light using optical waveguide innovation, discover how it works
- NEURA Robotics — Cognitive Robotics for Real-World Applications: NEURA Robotics enables safe and smart robot integration for Industry, Work and Everyday Life
GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.Its clients are individuals, familyoffices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.
Show more...Investment focus
- Industry: Information Technology, Medical, Software
- Stage:Seed, Series A
- Geography: Switzerland, Germany, United Kingdom
Investor stats
- Total investments: 164
- Round size: Seed $544k–$5M; Series A $1.2M–$10M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Stylect — Stylect is a mobile app to to help women discover their perfect shoe. They aggregate products from multiple websites and based on users' preferences (that they gather through a hot-or-not interface), they recommend better products. Their users are able to keep track of and buy the products they like and receive notifications whenever a productthey love goes on sale. Finally, They use geolocation to let their users know when a shoe is selling in a store nearby.
- Prestodiag — Prestodiag develops, manufactures and sells innovative solutions for rapid detection of bacteria. Their analytical solutions are based on an innovative optics technology called Surface Plasmon Resonance imaging and allow detection and identification of pathogenic bacteria such as Salmonella, Listeria or E.coli. They provide users with a result injust a few hours instead of 1 to several days. Their market is primarily the food safety sector, and also on medical and environmental applications.
- Arktis Radiation Detectors — Arktis develops and manufactures next generation systems that detect and categorize radiological and nuclear materials to enhance security and operations.
Thuja Capital invests in early stage medical product innovations for diagnosis, cure, care or prevention.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Seed
- Geography: The Netherlands, Belgium, United States
Investor stats
- Total investments: 54
- Lead/follow: no public data
Portfolio highlights
- Pan Cancer — Pan Cancer T is an immunotherapy company developing next-generation TCR-T cell therapies for solid cancer.
- Synerkine Pharma — Synerkine Pharma. Connecting Cytokines for the benefit of patients.
- Artica Therapeutics — Artica Therapeutics specializes in biotechnological research and development for medical devices, pharmaceutical processes, and food.
Health Care VC funding in Belgium at a glance
Stats across 402 deals from 405 investors.
Access all 405 VC funds in Belgium Health Care startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Health Care VC Funds in Belgium investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 405 VC funds investing in Belgium Health Care startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!